Organon & Co. (NYSE:OGN) Given Average Rating of "Reduce" by Brokerages

Key Points

• Organon & Co. holds an average “Reduce” rating from seven analysts, including two sells and five holds. The average 12-month price target is $11.40, below the stock’s recent price of $13.74.
• Several brokerages recently became more favorable, with BNP Paribas Exane and Piper Sandler moving to neutral ratings and raising their price targets to $14.00.
• Institutional investors own 77.43% of the company, while major firms including Goldman Sachs and Royal Bank of Canada increased their holdings. Organon also declared a quarterly dividend of $0.02 per share, for an annualized yield of 0.6%.

Shares of Organon & Co. (NYSE:OGN - Get Free Report) have been assigned an average rating of "Reduce" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $11.40.

Several brokerages have recently weighed in on OGN. BNP Paribas Exane reiterated a "neutral" rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Piper Sandler raised shares of Organon & Co. from an "underweight" rating to a "neutral" rating and upped their price target for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Finally, Weiss Ratings downgraded shares of Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday, August 3rd.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in OGN. Royal Bank of Canada increased its stake in Organon & Co. by 53.4% during the first quarter. Royal Bank of Canada now owns 360,862 shares of the company's stock worth $5,374,000 after acquiring an additional 125,648 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Organon & Co. by 126.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company's stock valued at $21,370,000 after acquiring an additional 801,307 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Organon & Co. by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company's stock valued at $15,530,000 after acquiring an additional 26,640 shares during the period. Focus Partners Wealth lifted its holdings in shares of Organon & Co. by 33.2% during the 1st quarter. Focus Partners Wealth now owns 55,875 shares of the company's stock valued at $832,000 after acquiring an additional 13,925 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Organon & Co. during the 2nd quarter valued at $107,000. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Trading Down 0.0%

NYSE:OGN traded down $0.01 during mid-day trading on Monday, reaching $13.74. The company's stock had a trading volume of 407,436 shares, compared to its average volume of 5,739,436. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44. The stock has a market cap of $3.61 billion, a P/E ratio of 17.85, a P/E/G ratio of 1.27 and a beta of 1.55. The company's fifty day simple moving average is $13.55 and its two-hundred day simple moving average is $10.92. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $13.76.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.'s dividend payout ratio is presently 10.39%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source